MannKind presents Afrezza study at scientific meeting
ORLANDO, Fla. An inhaled insulin made by MannKind for patients with Type 2 diabetes provides glycemic control comparable to standard treatments, but with less weight gain, according to results of a study the company will present Saturday at a scientific meeting.
MannKind will present the study of Afrezza (insulin human [rDNA origin]) at a special symposium co-hosted by medical journal The Lancet and the American Diabetes Association at the ADA’s 70th annual Scientific Sessions. The study also will appear in the June 26 issue of The Lancet. The study compared Afrezza added to basal insulin with standard insulin therapy in adult patients with Type 2 diabetes to assess its ability to control post-meal blood sugar levels.
“Insulin therapy is often a delayed strategy in patients with Type 2 diabetes because it is associated with weight gain, hypoglycemia and the need for subcutaneous injections,” Diabetes Control Foundation executive and study co-author Daniel Lorber said. “Our findings show that mealtime Afrezza, in combination with once-daily injected glargine, provides equivalent glucose control with fewer injections, less hypoglycemia and less weight gain than does twice-a-day premixed insulin.”
Duracell launches myGrid mobile device chargers
BETHEL, Conn. Duracell has expanded its Smart Power line with a new product designed to charge the latest mobile devices.
New myGrid kits now are available for Apple products and smart phones with micro-USB ports. The kits allow devices to wirelessly charge, eliminating the frustration of having multiple charging cords that can clutter up the home or office space and take up electrical outlets.
“Consumers today want a simpler way of charging the devices that are vital to their day-to-day lives. With new devices being introduced at a rapid pace, we’re bringing consumers new innovations to help realize their personal power needs,” said Rick June, Duracell VP and general manager, North America.
Martindale succeeds Standley as Rite Aid’s COO
CAMP HILL, Pa. Rite Aid on Thursday promoted Ken Martindale to COO, succeeding John Standley who was promoted to president and CEO following the Rite Aid annual meeting conducted Wednesday.
“In a very short time, [Martindale] has had a significant impact on a number of the initiatives we’re implementing to improve our performance and grow profitable sales, including the launch of our new customer loyalty program Wellness+, the revamping and expansion of our private brand program and our segmentation strategies for low volume stores,” Standley said. “Add to that his first hand experience in store operations during his extensive retail career, and Rite Aid has a very talented and accomplished new COO.”
Martindale will have overall responsibility for all store operations as well as category management, marketing, merchandising and supply chain. Martindale was senior EVP merchandising prior to the promotion.
Martindale, 50, joined Rite Aid in December 2008. Previously, he served as co-president, chief merchandising and marketing officer for Pathmark prior to that company’s sale to A&P. Martindale started his retail career in 1975 with Smith’s Food and Drug Centers, where he climbed the ladder from a district manager in store operations to SVP marketing and SVP sales and merchandising. In January 1998, he joined Fred Meyer where he served as EVP sales and procurement.
During his retail career, Martindale also founded and operated Orchard Street Inc. a food retailer in Salt Lake City; consulted for national and regional food retailers on category management, marketing and strategic planning; and served as president, CEO and chairman of Intesource Inc., a software company designed to help food and drug retail, wholesale and manufacturing clients with procurement.